Posted inClinical Updates Oncology
Divarasib Compared with Sotorasib and Adagrasib in KRAS G12C-Mutated NSCLC: A Comprehensive Clinical and Translational Review
This review synthesizes phase 3 clinical evidence comparing divarasib, sotorasib, and adagrasib for KRAS G12C-mutated NSCLC, highlighting divarasib's superior efficacy and safety, dose optimization insights, real-world data, and translational biomarker findings.
